+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Artificial Intelligence for Enhanced Diagnosis in Oncology

  • Book

  • May 2026
  • Elsevier Science and Technology
  • ID: 6251579

"Artificial Intelligence for Enhanced Diagnosis in Oncology� explores the transformative role of AI in cancer care, examining its applications across various domains. The book introduces key AI technologies, such as machine learning and natural language processing, and discusses the challenges and opportunities they present in oncology. Each chapter focuses on specific areas where AI has significant impact, including early cancer screening, diagnosis, pathology, surgical oncology, and imaging. Readers will learn how AI improves precision in treatment, optimizes clinical trial designs, and accelerates drug discovery while addressing critical issues like predicting adverse drug reactions and assessing cancer risks. Emphasizing personalized oncology, the book also highlights innovative approaches to patient education and engagement. Concluding with insights on emerging trends and ethical considerations, this resource is essential for researchers, clinicians, and healthcare professionals committed to advancing cancer care through AI technologies.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

1 Artificial intelligence in oncology: An introduction
2 AI in early cancer screening
3 AI in cancer diagnosis and prognosis
4 AI-driven pathology: Transforming histopathological analysis
5 Integrating liquid biopsy and artificial intelligence for precision detection of cancer signatures
6 AI in surgical oncology
7 Artificial intelligence in cancer imaging
8 Artificial intelligence and radiomics in precision oncology
9 AI in cancer clinical trials enhancing study design and patient selection
10 AI in designing novel cancer treatments
11 Artificial intelligence for personalized oncology: Tailoring treatments to individual patients
12 Artificial intelligence in predicting adverse drug reactions, surgical outcomes, and radiotherapy responses
13 Artificial intelligence in cancer risk assessment
14 Artificial intelligence for oncology sepsis risk and mortality prediction
15 AI in cancer education and screening: Improving patient awareness and quality of life
16 The future of AI in oncology: Trends and innovations

Authors

Gowhar Rashid Assistant Professor, Department of Medical Lab Technology at Amity Medical School, Amity University-Gurugram, India.. Dr. Gowhar Rashid is an Assistant Professor in the Department of Medical Lab Technology at Amity Medical School, Amity University-Gurugram, India. He earned his PhD in Biochemistry from the Sher-I-Kashmir Institute of Medical Sciences, focusing on the genetic susceptibility of colorectal cancer. Dr. Rashid has a strong background in laboratory sciences, molecular biology, and clinical biochemistry, with extensive research experience in cancer genetics and biomarkers. He has published numerous research papers and book chapters, contributing significantly to the field. Additionally, he serves on the editorial board for various journals and is a member of several professional organizations, including the European Society for Medical Oncology. Dr. Rashid is actively involved in research and teaching, aiming to advance knowledge in medical laboratory technology and its applications in healthcare. His expertise includes molecular techniques, data analysis, and bioinformatics, making him a valuable asset to the academic community. Zainab Siddiqui Era University, India. Dr. Siddiqui is a prominent medical researcher specializing in cancer biology, with a growing focus on in-silico techniques such as molecular docking, ADMET analysis, and homology modeling. Her recent work has garnered invitations to speak at prestigious events, including the World Congress on Cancer Research (WCCN-2023) and the Inspiring Women in Scientific Academia event by Altem Technologies. During her PhD, she investigated cancer stem cells and their regulation by the tumor microenvironment, laying the groundwork for her current research using 3D bioprinting to identify molecular targets for therapy. In addition to her research, Dr. Siddiqui is an active member of the Editorial Board for Era's Journal of Medical Research and the Asian Pacific Journal of Cancer Prevention, where she plays a crucial role in the peer-review process, ensuring the dissemination of high-quality research in the field of cancer prevention and treatment. Ashwin Kotnis All India Institute of Medical Sciences, India. Prof. Ashwin Kotnis is trained in biochemistry, genetics, and immunology of cancer from prestigious institutions, including MS University Baroda, Tata Memorial Centre, Karolinska Institute, and the University of Oxford. His interdisciplinary research focuses on DNA repair, nutrition, and predisposition to head and neck cancer, vitiligo, and primary immunodeficiency diseases, supported by various organizations such as ICMR and DST. He leads a research team that publishes extensively and aims to develop personalized therapies and affordable diagnostic methods. A FAIMER fellow in medical education, Prof. Kotnis is a popular teacher known for innovative teaching methods and research ethics. As the founder member secretary of the Ethics Committee at AIIMS Bhopal, he serves on several editorial boards and ethics panels. He is dedicated to public awareness on vitiligo and co-founded Apna School, a charity initiative supporting the education of children of construction laborers, earning significant public recognition. Wael Hafez Medical Research and clinical studies institute, The National Research Centre, Cairo, Egypt. Dr. Wael Hafez graduated from Zagazig University and trained at Cairo University School of Medicine, earning his Master's and Doctorate in Internal Medicine. Since joining the National Research Center of Egypt in 2004, he has focused on applying medical research to internal medicine, including virology, genetics, public health, and noncommunicable diseases. During the COVID-19 pandemic in 2020, Dr. Hafez led the management team at NMC Royal Hospital in Abu Dhabi, where he treated over 2,000 patients and contributed to pandemic task force meetings. He is currently the principal investigator for several studies investigating the pathogenesis, severity, and outcomes of COVID-19. Dr. Hafez's work continues to impact the field of internal medicine and public health through his research and clinical leadership.